Contact us today for a FREE no-obligation initial consultation

law done differently!



anuvia, Janumet and Onglyza Do Not Cut Death Risk, Researchers Say

Januvia, Janumet and Onglyza Do Not Cut Death Risk, Researchers Say

By | Byetta, Januvia, Victoza

Januvia, along with Janumet and Onglyza (two other type 2 diabetes drugs in its class) do not reduce the risk of death when compared to other types of medications to treat the condition.

That’s according to new research published in the Journal of the American Medical Association by scientists at the Imperial College London.

These findings are noteworthy especially in light of persistent concerns that DPP-4 inhibitors (dipeptidyl peptidase 4 inhibitors) like Januvia (sitagliptin), Janumet (pose an enhanced risk of pancreatic cancer. The alleged failure of Januvia and Janumet manufacturer Merck & Co. to warn of this risk has been the subject of ongoing litigation. These drugs in particular were approved in 2006 and 2007, respectively, though Janumet has the highest-risk “black box warning” for lactic acidosis (due to the fact that it contains metformin).

Of course, all drugs have risks and those with type 2 diabetes face severe consequences of that condition, so could be willing to take on those risks anyway – but they must be made aware and fairly warned about it so they and their doctors can make an informed decision. Now, this new study suggests that despite being top-sellers of diabetes drugs, neither Janumet nor Januvia lowered the risk of death among patients.  Read More

Conflicting Reports on Pancreatic Cancer Risk for Diabetes Drug Patients

By | Januvia

Diabetes Drugs

Supporting research – and pending litigation – alleging Type 2 diabetes drugs Januvia / Janumet are a catalyst for causing pancreatic cancer continue to raise concern for the millions of Americans taking these medications. Other diabetes drugs Victoza and Byetta , also DDP-4 inhibitors, are also alleged to act in much the same way. Januvia injury

Now, in a new study, researchers at Rutgers Cancer Institute of New Jersey have concluded that metformin (an ingredient used in Janumet that makes it different from Januvia) might be an effective treatment in the battle against pancreatic cancer. Metformin is also sold under brand names Glumetza, Glucophage and Fortamet. Note: This analysis isn’t the first to posit that metformin might be part of the solution in slowing and treating pancreatic cancer; that theory has been floated for a while in various research circles. It is however the first that delves into the hypothesis that the diabetes drug can do so by impacting the REarranged during Transfection (RET) cell signaling pathway. In more simple terms, the drug reportedly targets and kills cancer cells, controlling inflammation responses and blocking signaling pathways.

However, we must stress this research is still inconclusive, and the medical community is not in agreement about metformin’s use as an anti-cancer agent. Doctors at the Mayo Clinic Cancer Center published research in 2015, as explained by the American Association for Cancer Research, concluding metformin did NOT improve survival rates of patients with pancreatic cancer. The lead researcher stated his findings underscored the importance of making sure retrospective studies – those that look at rates of pancreatic cancer and diabetes drug usage – are appropriately designed and that new studies are based on solid rationale.  Read More